Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes

Michael Kongnyuy; Arvin K. George; Ardeshir R. Rastinehad; Peter A. Pinto

doi:10.1007/s11934-016-0589-z

Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes

Michael Kongnyuy, Arvin K. George, Ardeshir R. Rastinehad, Peter A. Pinto

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Review article › peer-review

62 Scopus citations

Abstract

Transrectal ultrasound (TRUS)-guided (12–14 core) systematic biopsy of the prostate is the recommended standard for patients with suspicion of prostate cancer (PCa). Advances in imaging have led to the application of magnetic resonance imaging (MRI) for the detection of PCa with subsequent development of software-based co-registration allowing for the integration of MRI with real-time TRUS during prostate biopsy. A number of fusion-guided methods and platforms are now commercially available with common elements in image and analysis and planning. Implementation of fusion-guided prostate biopsy has now been proven to improve the detection of clinically significant PCa in appropriately selected patients.

Original language	English
Article number	32
Pages (from-to)	1-9
Number of pages	9
Journal	Current Urology Reports
Volume	17
Issue number	4
DOIs	https://doi.org/10.1007/s11934-016-0589-z
State	Published - 1 Apr 2016

Keywords

Biopsy
Magnetic resonance imaging
Prostate cancer
Transrectal ultrasound

Access to Document

10.1007/s11934-016-0589-z

Cite this

@article{e3675d9111dd4cddabd82cae790dfb34,

title = "Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes",

abstract = "Transrectal ultrasound (TRUS)-guided (12–14 core) systematic biopsy of the prostate is the recommended standard for patients with suspicion of prostate cancer (PCa). Advances in imaging have led to the application of magnetic resonance imaging (MRI) for the detection of PCa with subsequent development of software-based co-registration allowing for the integration of MRI with real-time TRUS during prostate biopsy. A number of fusion-guided methods and platforms are now commercially available with common elements in image and analysis and planning. Implementation of fusion-guided prostate biopsy has now been proven to improve the detection of clinically significant PCa in appropriately selected patients.",

keywords = "Biopsy, Magnetic resonance imaging, Prostate cancer, Transrectal ultrasound",

author = "Michael Kongnyuy and George, {Arvin K.} and Rastinehad, {Ardeshir R.} and Pinto, {Peter A.}",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York (outside the USA).",

year = "2016",

month = apr,

day = "1",

doi = "10.1007/s11934-016-0589-z",

language = "English",

volume = "17",

pages = "1--9",

journal = "Current Urology Reports",

issn = "1527-2737",

publisher = "Current Science, Inc.",

number = "4",

}

TY - JOUR

T1 - Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy

T2 - Review of Technology, Techniques, and Outcomes

AU - Kongnyuy, Michael

AU - George, Arvin K.

AU - Rastinehad, Ardeshir R.

AU - Pinto, Peter A.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Transrectal ultrasound (TRUS)-guided (12–14 core) systematic biopsy of the prostate is the recommended standard for patients with suspicion of prostate cancer (PCa). Advances in imaging have led to the application of magnetic resonance imaging (MRI) for the detection of PCa with subsequent development of software-based co-registration allowing for the integration of MRI with real-time TRUS during prostate biopsy. A number of fusion-guided methods and platforms are now commercially available with common elements in image and analysis and planning. Implementation of fusion-guided prostate biopsy has now been proven to improve the detection of clinically significant PCa in appropriately selected patients.

AB - Transrectal ultrasound (TRUS)-guided (12–14 core) systematic biopsy of the prostate is the recommended standard for patients with suspicion of prostate cancer (PCa). Advances in imaging have led to the application of magnetic resonance imaging (MRI) for the detection of PCa with subsequent development of software-based co-registration allowing for the integration of MRI with real-time TRUS during prostate biopsy. A number of fusion-guided methods and platforms are now commercially available with common elements in image and analysis and planning. Implementation of fusion-guided prostate biopsy has now been proven to improve the detection of clinically significant PCa in appropriately selected patients.

KW - Biopsy

KW - Magnetic resonance imaging

KW - Prostate cancer

KW - Transrectal ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85017068555&partnerID=8YFLogxK

U2 - 10.1007/s11934-016-0589-z

DO - 10.1007/s11934-016-0589-z

M3 - Review article

C2 - 26902626

AN - SCOPUS:85017068555

SN - 1527-2737

VL - 17

SP - 1

EP - 9

JO - Current Urology Reports

JF - Current Urology Reports

IS - 4

M1 - 32

ER -

Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes

Abstract

Keywords

Access to Document

Fingerprint

Cite this